Despite its benefits, there are challenges associated with the use of fidaxomicin. One of the primary concerns is its cost, which can be significantly higher than other antibiotics. This can limit its accessibility and widespread use, particularly in resource-limited settings. Furthermore, while fidaxomicin is effective against C. difficile, it is not a broad-spectrum antibiotic and thus not suitable for treating other types of bacterial infections.
